Periodic Reporting for period 1 - QUANTUM-TOX (QUANTUM-TOX - Revolutionizing Computational Toxicology with Electronic Structure Descriptors andArtificial Intelligence)
Período documentado: 2024-02-01 hasta 2025-01-31
A desirable computational toxicology framework should offer broader coverage of chemical space while using a small number of interpretable descriptors. The QUANTUM-TOX consortium is addressing these limitations by developing a next-generation fingerprint that moves beyond conventional structure-based predictions. Instead of relying solely on molecular structures, the new approach leverages electronic structure information to provide a more fundamental and transferable representation of chemical behavior. By incorporating quantum-mechanical descriptors, this fingerprint aims to enhance the accuracy of toxicity predictions and overcome the limitations of existing models, ultimately improving the reliability and applicability of computational toxicology.
- Finalized chemicals for skin sensitization
- Initial geometries obtained and reviewed by UNIMAN through scans to conduct prelim testing. This has aided in WP2 specific goals in developing the quantum chemical descriptors and methodologies.
- Perturbations and Descriptors of Covalent Binding completed. Reactivity analysis, CDFT analysis, and initial validation using multiple linear regression were done by FCC to ensure the performance of the computational methodologies .
- An AI system to analyze discrete-valued data, linking features of electronic signatures (ESigns) to toxicity experimental endpoints using least-squares regression was done by FCC.
- Work has started on development and use of QSAR models to compare results with QM by LJMU.
All the participants are working towards technical development of the project. Apart from this, regular communication and dissemination work is being done regularly to exploit the results and gain market visibility.
In addition to its planned initiatives, the consortium actively engages in outreach efforts with key stakeholders, including the pharmaceutical industry and organizations specializing in in vitro toxicity research. Partnering with pharmaceutical companies is important for gaining access to proprietary data and ensuring that the project’s software aligns with the companies’ protocols and workflows. Collaboration with in vitro research institutions helps develop standardized in silico/in vitro methods that improve predictive accuracy and streamline risk assessment processes. These interactions strengthen the project’s applicability and ensure its tools meet real-world scientific and regulatory needs.